136 related articles for article (PubMed ID: 14720216)
1. Loss of alpha-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum.
Quik M; Bordia T; Forno L; McIntosh JM
J Neurochem; 2004 Feb; 88(3):668-79. PubMed ID: 14720216
[TBL] [Abstract][Full Text] [Related]
2. Selective recovery of striatal 125I-alpha-conotoxinmii nicotinic receptors after nigrostriatal damage in monkeys.
Lai A; Sum J; Fan H; McIntosh JM; Quik M
Neuroscience; 2004; 127(2):399-408. PubMed ID: 15262330
[TBL] [Abstract][Full Text] [Related]
3. Loss of nicotinic receptors in monkey striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment is due to a decline in alpha-conotoxin MII sites.
Kulak JM; McIntosh JM; Quik M
Mol Pharmacol; 2002 Jan; 61(1):230-8. PubMed ID: 11752225
[TBL] [Abstract][Full Text] [Related]
4. Differential nicotinic receptor expression in monkey basal ganglia: effects of nigrostriatal damage.
Quik M; Polonskaya Y; McIntosh JM; Kulak JM
Neuroscience; 2002; 112(3):619-30. PubMed ID: 12074903
[TBL] [Abstract][Full Text] [Related]
5. Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine.
Bordia T; Parameswaran N; Fan H; Langston JW; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2006 Oct; 319(1):285-92. PubMed ID: 16837557
[TBL] [Abstract][Full Text] [Related]
6. Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice.
Quik M; Sum JD; Whiteaker P; McCallum SE; Marks MJ; Musachio J; McIntosh JM; Collins AC; Grady SR
Mol Pharmacol; 2003 May; 63(5):1169-79. PubMed ID: 12695545
[TBL] [Abstract][Full Text] [Related]
7. L-DOPA treatment modulates nicotinic receptors in monkey striatum.
Quik M; Bordia T; Okihara M; Fan H; Marks MJ; McIntosh JM; Whiteaker P
Mol Pharmacol; 2003 Sep; 64(3):619-28. PubMed ID: 12920198
[TBL] [Abstract][Full Text] [Related]
8. Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum.
Bordia T; Grady SR; McIntosh JM; Quik M
Mol Pharmacol; 2007 Jul; 72(1):52-61. PubMed ID: 17409284
[TBL] [Abstract][Full Text] [Related]
9. Cholinergic nicotinic receptor involvement in movement disorders associated with Lewy body diseases. An autoradiography study using [(125)I]alpha-conotoxinMII in the striatum and thalamus.
Bohr IJ; Ray MA; McIntosh JM; Chalon S; Guilloteau D; McKeith IG; Perry RH; Clementi F; Perry EK; Court JA; Piggott MA
Exp Neurol; 2005 Feb; 191(2):292-300. PubMed ID: 15649484
[TBL] [Abstract][Full Text] [Related]
10. Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage.
McCallum SE; Parameswaran N; Bordia T; McIntosh JM; Grady SR; Quik M
Mol Pharmacol; 2005 Sep; 68(3):737-46. PubMed ID: 15933214
[TBL] [Abstract][Full Text] [Related]
11. 5-Iodo-A-85380 binds to alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as alpha4beta2* subtypes.
Kulak JM; Sum J; Musachio JL; McIntosh JM; Quik M
J Neurochem; 2002 Apr; 81(2):403-6. PubMed ID: 12064487
[TBL] [Abstract][Full Text] [Related]
12. Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.
Quik M; Polonskaya Y; Kulak JM; McIntosh JM
J Neurosci; 2001 Aug; 21(15):5494-500. PubMed ID: 11466420
[TBL] [Abstract][Full Text] [Related]
13. Declines in different beta2* nicotinic receptor populations in monkey striatum after nigrostriatal damage.
Kulak JM; Musachio JL; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2002 Nov; 303(2):633-9. PubMed ID: 12388645
[TBL] [Abstract][Full Text] [Related]
14. α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease.
Perez XA; Bordia T; McIntosh JM; Quik M
Mol Pharmacol; 2010 Nov; 78(5):971-80. PubMed ID: 20732972
[TBL] [Abstract][Full Text] [Related]
15. Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy.
Quik M; McIntosh JM
J Pharmacol Exp Ther; 2006 Feb; 316(2):481-9. PubMed ID: 16210393
[TBL] [Abstract][Full Text] [Related]
16. Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice.
Champtiaux N; Han ZY; Bessis A; Rossi FM; Zoli M; Marubio L; McIntosh JM; Changeux JP
J Neurosci; 2002 Feb; 22(4):1208-17. PubMed ID: 11850448
[TBL] [Abstract][Full Text] [Related]
17. Long-term nicotine treatment decreases striatal alpha 6* nicotinic acetylcholine receptor sites and function in mice.
Lai A; Parameswaran N; Khwaja M; Whiteaker P; Lindstrom JM; Fan H; McIntosh JM; Grady SR; Quik M
Mol Pharmacol; 2005 May; 67(5):1639-47. PubMed ID: 15681595
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease.
Schmaljohann J; Gündisch D; Minnerop M; Bucerius J; Joe A; Reinhardt M; Guhlke S; Biersack HJ; Wüllner U
Nucl Med Biol; 2006 Apr; 33(3):305-9. PubMed ID: 16631078
[TBL] [Abstract][Full Text] [Related]
19. [Possible involvement of neuronal nicotinic acetylcholine receptors in compensatory brain mechanisms at early stages of Parkinson's disease].
Kryukova EV; Shelukhina IV; Kolacheva AA; Alieva AK; Shadrina MI; Slominsky PA; Kasheverov IE; Utkin YN; Ugrumov MV; Tsetlin VI
Biomed Khim; 2017 May; 63(3):241-247. PubMed ID: 28781257
[TBL] [Abstract][Full Text] [Related]
20. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum.
Kaufman MJ; Madras BK
Synapse; 1991 Sep; 9(1):43-9. PubMed ID: 1796351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
